MK-677 vs Ipamorelin vs CJC-1295: GH Secretagogue Triple Comparison

The study of growth hormone (GH) secretion employs compounds spanning three distinct chemical classes: non-peptide small molecules, synthetic peptides targeting the ghrelin receptor, and modified GHRH analogs. MK-677 (Ibutamoren), Ipamorelin, and CJC-1295 each represent one of these classes, offering researchers complementary tools for investigating GH axis physiology. Their divergent structures produce fundamentally different pharmacokinetic and physicochemical profiles, making compound selection a critical experimental design decision [1][2][3].

Understanding these differences is essential for selecting appropriate controls, analytical methods, and storage protocols. A researcher studying GHS-R1a signaling would choose differently than one investigating GHRH-R pathway kinetics or seeking an orally bioavailable tool compound.

MK-677 (Ibutamoren mesylate) is a spiropiperidine sulfonamide with molecular formula C27H36N4O5S·CH4O3S and a molecular weight of approximately 528.67 Da (free base). It is a non-peptide compound, meaning it lacks amide-bonded amino acid residues. Its benzyl-sulfonyl and indoline moieties create a three-dimensional pharmacophore that mimics the spatial arrangement of ghrelin at the GHS-R1a binding site [1].

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide of ~711.85 Da. It incorporates alpha-aminoisobutyric acid (Aib) and D-configured residues for enzymatic resistance. Unlike MK-677, it retains a peptide backbone with characteristic amide bonds, making it susceptible (though resistant) to peptidases [2].

CJC-1295 is a synthetic 30-amino-acid GHRH analog (modifications at positions 2, 8, 15, and 27 of GHRH(1-29)NH2) with a molecular weight of approximately 3,367.97 Da. The DAC (Drug Affinity Complex) variant includes a maleimidopropionic acid linker enabling covalent albumin binding, dramatically extending its circulation time in biological systems. The non-DAC variant (also called Modified GRF 1-29) retains the four amino acid substitutions without the DAC moiety [3][4].

MK-677 and Ipamorelin both bind GHS-R1a, but their binding modes differ. MK-677 occupies a deep binding pocket in the transmembrane domain, engaging hydrophobic residues in TM3, TM5, TM6, and TM7. Its non-peptide scaffold enables oral absorption across the GI epithelium. Ipamorelin binds a partially overlapping but distinct epitope, with the D-2-Nal residue providing critical pi-stacking interactions. Both activate Gαq/11 → PLC → IP3 → Ca²⁺ signaling [1][2].

CJC-1295 activates the GHRH receptor (GHRH-R), a class B GPCR. Binding triggers Gαs-coupled adenylyl cyclase activation, increasing intracellular cAMP and driving PKA-mediated GH transcription and release. This is mechanistically independent of the GHS pathway—CJC-1295 and Ipamorelin/MK-677 stimulate GH through parallel, non-redundant receptor systems [3][5].

The molecular weight range spans nearly seven-fold: MK-677 at ~528 Da, Ipamorelin at ~711 Da, and CJC-1295 at ~3,368 Da. This disparity produces significant differences in solubility behavior, diffusion rates, and chromatographic retention. MK-677, as a small organic molecule, exhibits lipophilic character (LogP ~2.1) and is freely soluble in DMSO and methanol. Ipamorelin is amphiphilic with aqueous solubility at mildly acidic pH. CJC-1295 behaves as a typical medium-sized peptide with pH-dependent solubility driven by its multiple charged residues [1][2][3].

Container adsorption is most problematic for CJC-1295 at low concentrations due to its large surface area and amphiphilic segments. Silanized glassware or low-binding polypropylene is recommended. MK-677 shows minimal adsorption issues. Ipamorelin exhibits intermediate behavior.

MK-677 is the most chemically stable of the three, as expected for a non-peptide compound. Solid-state MK-677 mesylate is stable at room temperature for months and at -20°C for years. It lacks peptide bonds, eliminating hydrolysis, deamidation, and oxidation pathways common to peptides. Solutions in DMSO remain stable for >12 months at -20°C [1].

Ipamorelin's D-amino acid substitutions and Aib residue confer good stability among peptides. Lyophilized material retains >98% purity for >24 months at -20°C. Reconstituted solutions at pH 4.5-6.5 are stable for 3-4 weeks at 2-8°C [2].

CJC-1295 is the most stability-sensitive due to its larger size and multiple modification sites. The DAC variant's maleimide linker is susceptible to hydrolysis and retro-Michael reactions. Lyophilized CJC-1295 (no DAC) at -20°C is stable for ~18-24 months. Solutions require pH control (5.0-6.5) and should be used within 1-2 weeks of reconstitution. The Ala2 substitution (replacing native Asp2) eliminates DPP-IV cleavage but introduces altered aggregation behavior [3][6].

MK-677 is unique among these three compounds in possessing oral bioavailability. Its small molecular size, lipophilicity, and non-peptide nature allow absorption across the gastrointestinal epithelium. Oral bioavailability in preclinical models exceeds 60%. This eliminates the need for parenteral administration, simplifying dosing protocols in research settings [1].

Both Ipamorelin and CJC-1295 require parenteral (typically subcutaneous) administration due to their peptide nature. Ipamorelin's small size (5 aa) does not confer sufficient oral stability, as gastric acid and pepsin rapidly degrade even D-amino acid-containing peptides of this class. CJC-1295's 30-residue chain has negligible oral bioavailability [2][3].

MK-677 is best analyzed by LC-MS/MS using electrospray ionization. Its [M+H]+ at m/z 529.2 provides a strong precursor ion for MRM transitions. RP-HPLC with C18 columns and isocratic or shallow gradient elution (60-80% ACN) resolves MK-677 from common matrix interferences. UV detection at 230 nm is feasible but less specific [1][6].

Ipamorelin analysis uses RP-HPLC (C18, 15-50% ACN gradient) with UV detection at 220/282 nm (D-2-Nal absorbance). ESI-MS confirms [M+H]+ = 711.9 m/z. For CJC-1295, larger-pore C4 or C8 columns with wider gradients (20-70% ACN) are preferred. ESI-MS shows multiply charged species at [M+3H]3+ = 1123.7 and [M+4H]4+ = 843.0. Size-exclusion chromatography can monitor aggregation [2][3][6].

MK-677 shows moderate selectivity for GHS-R1a but, at high concentrations, can engage off-target receptors. Studies have documented appetite-stimulating effects consistent with hypothalamic GHS-R1a activation and transient increases in cortisol and prolactin at supratherapeutic exposures. Its long half-life (~5 hours) means sustained receptor occupancy [1][5].

Ipamorelin demonstrates the highest GH selectivity among GHRPs, with minimal ACTH, prolactin, or cortisol stimulation at GH-effective concentrations. CJC-1295 acts exclusively through the GHRH-R pathway and does not cross-activate GHS-R1a, corticotroph, or lactotroph signaling. The DAC variant's extended exposure may produce more sustained somatotroph stimulation compared to pulsatile GHRH physiology [2][4][7].

Q: Can MK-677, Ipamorelin, and CJC-1295 be combined in research protocols? A: Yes, they target independent receptor systems (GHS-R1a for MK-677 and Ipamorelin; GHRH-R for CJC-1295). Combining a GHS-R1a agonist with a GHRH-R agonist is a standard approach for studying synergistic GH release in experimental models.

Q: Which compound is most suitable for oral dosing studies? A: Only MK-677 has oral bioavailability. Ipamorelin and CJC-1295 are peptides requiring parenteral administration. Oral formulations of peptides remain an active area of pharmaceutical research but are not standard for these compounds.

Q: How do storage requirements differ? A: MK-677 is the least demanding (stable as solid at room temperature). Ipamorelin requires -20°C lyophilized storage. CJC-1295 is most sensitive, requiring -20°C storage with careful reconstitution and prompt use of solutions.

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• CJC-1295: Complete Research Guide → /learn/cjc-1295-no-dac
• Ipamorelin: Complete Research Guide → /learn/ipamorelin
• MK-677 (Ibutamoren): Complete Research Guide → /learn/mk-677-ibutamoren-research-guide-chemical-profile

• Read more: Ipamorelin vs GHRP-6: Growth Hormone Secretagogue Head-to-Head → https://www.chemverify.com/learn/ipamorelin-vs-ghrp-6-secretagogue-comparison
• Read more: MK-677 vs. Ipamorelin: Oral GHS vs. Injectable GHRP Comparison → https://www.chemverify.com/learn/mk-677-vs-ipamorelin
• Read more: Sermorelin vs Ipamorelin: GHRH Analog vs GHRP Compared → https://www.chemverify.com/learn/sermorelin-vs-ipamorelin-ghrh-vs-ghrp
• Read more: CJC-1295 vs. Ipamorelin: GHRH Analog vs. GHRP Comparison → https://www.chemverify.com/learn/cjc-1295-vs-ipamorelin